Newer Therapies References

Abbvie Press Release. U.S. FDA Expands IMBRUVICA® (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients. Available at https://news.abbvie.com/news/us-fda-expands-imbruvica-ibrutinib-label-to-include-overall-survival-data-in-previously-untreated-chronic-lymphocytic-leukemia-cll-and-new-indication-for-small-lymphocytic-lymphoma-sll-patients.htm. Accessed: November 2017.

Abramson JS, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, et al. Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study. J Clin Oncol 2015;33 suppl: Abstract 7082.

Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(9):2977–86.

Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism. Blood. 2016;127(25):3215–24.

Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31(5):584–91.

Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015;29(9):1811–22.

Barr PM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol 2015;33(Suppl):Abstract 7012.

Barrientos J, Coutre S, De Vos S, Finn I, Wagnder-Johnston ND, Schreeder MT, et al. Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation. J Clin Oncol 2015;33 suppl: Abstract 7011.

Barrientos JC, Wagner-Johnston ND, De Vos S, Coutre SE, Schreeder MT, Flinn I, et al. Chemoimmunotherapy combination of idelalisib with bendamustine/rituximab or chlorambucil/rituximab in patients with relapsed/refractory CLL demonstrates efficacy and tolerability. Blood. 2013;122(21):4176.

Barrientos JC, Furman RR, Leonard J, Flinn I, Rai KR, De Vos S, et al. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol. 2013;(31):Abstract 7017.

Bauer A. Cancer Advance of the Year: Transformation of CLL Treatment. Available at: http://www.cancer.net/blog/2015-01/cancer-advance-year-transformation-cll-treatment. Accessed: November 2017.

Blum KA, Jones JA, Andritsos L, Flynn JM, Deam D, Heerema NA, et al. Phase 1 trial of flavopiridol and lenalidomide in patients with previously treated chronic lymphocytic leukemia (CLL). Blood. 2010 (ASH Annual Meeting)116(21):Abstract 2472.

Blunt MD, Steele AJ. Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukemia. Leuk Res Rep. 2015;4(2):60–3.

Brown JR, Abramson J, Hochberg E, Mikler E, Dalton V, Werner L, et al. A Phase I Study of Lenalidomide in Combination with Fludarabine and Rituximab in Previously Untreated CLL/SLL. Leukemia. 2010;24(11):1972–5.

Brown J, Barrientos J, Barr P, Flinn I, Burger J, Salmon Z, et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. Blood. 2013;122:525.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390–7.

Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy N, Coutre S, et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the Phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124(21):Abstract 3331.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2017 Jun 8. doi: 10.1038/leu.2017.175. [Epub ahead of print]

Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15(10):1090–9.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukaemia. N Engl J Med. 2015;373:2425–37.

Burger JA, Sivina M, Ferrajoli A, Jain N, Kim E, Kadia T, et al. 427 Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual meeting December 2017. Abstract available at: https://ash.confex.com/ash/2017/webprogram/Paper107661.html (Accessed December 2017)

Byrd JC, Furman R, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–2506.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al., Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

Byrd JC, Jones J, Woyach J A, Johnson AJ, Flynn JM. Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. J Clin Oncol. 2014;32(27):3039–47.

Bühler A, Wendtner CM, Kipps TJ, Rassenti L , Fraser GA, Michallet AS, Hillmen P, et al. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016;6:e404.

Burris HA, Patel MR, Fenske TS, O’Conner OA, Deng C, Brnader DM, et al. Clinical activity and safety profile of TGR-1202, a novel once daily PI3Kδ inhibitor, in patients with CLL and B-cell lymphoma. J Clin Oncol. 2015;33(suppl):Abstract 7069.

Castro JE, Loria OJ, Aguillon RA, James D, Llanos CA, Rassenti L, et al. A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens. (ASH Annual Meeting) 2007;110:Abstract 3119.

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–11.

Chanan-Khan AA, Czuczman MS, Padmanabhan S, Keating MJ, O’Brien SM, Wierda WG, et al. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients [abstract]. Blood. 2007 (ASH Annual Meeting);110(11):Abstract 3108.

Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343–9.

Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid. 2013;8:37–45.

Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, et al., Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 2017;23(5):1149-1155.

Coutre SE, Leonard JP, Furman RR, Barrientos JC, de Vos S, Flinn IW, et al. Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL): Results From a Phase I Study. Blood. 2012 (ASH Annual Meeting). 120:Abstract 191.

Crassini K, Stevenson W, Mulligan S, O. Giles Best. The MEK1/2 inhibitor binimetinib has cytotoxic and cytostatic effects and potentiates the actions of the BH3-mimetic ABT-737 against CLL cells under conditions that mimic the tumour microenvironment. XVI International Workshop on Chronic Lymphocytic Leukemia 2015; Abstract 11.

Davids MS, Gerecitano JF, Potluri J, Cerri E, Kim SY, Steinberg M, et al. Integrated safety analysis of venetoclax monotherapy in chronic lymphocytic leukemia (CLL). Clin Oncol 2016;34 suppl:Abstract 7528.

De Vos S, Furman RR, Barrientos JC, Wagner-Johnston ND, Flinn I, Sharman JP, et al. Idelalisib, a selective inhibitor of PI3Kδ, in combination with bendamustine, fludarabine or chlorambucil in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Blood. 2013;122(21): Abstract 2878.

Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124(24):3583–6.

Egle A, Steurer M, Gassner FJ, Geisberger R, Melchardt T, Pleyer L, et al., Lenalidomide/rituximab maintenance after induction with fludarabine/rituximab in combination with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): The Revlirit CLL5 AGMT phase I/II study, final results. Blood 2013 122:4164.

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v78–v84. e-update available from http://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Lymphocytic-Leukaemia/eUpdate-Treatment-Recommendations. Accessed: November 2017.

Efremov DG, Laurenti L. Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia. Prilozi. 2014;35(3):105–20.

EMA. CHMP Summary of opinion: ibrutinib. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003791/WC500205390.pdf. Accessed: November 2017.

EMA. CHMP confirms recommendations for use of Zydelig. 22 July 2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zydelig_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500210864.pdf. Accessed: November 2017.

FDA. FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in Combination with other Cancer Medicines. Available at http://www.fda.gov/Drugs/DrugSafety/ucm490618.htm. Accessed: November 2017.

FDA. FDA approves new treatment for adults with mantle cell lymphoma. Available at: https://www.astrazeneca.com/media-centre/press-releases/2017/us-fda-approves-astrazenecas-calquence-acalabrutinib-for-adult-patients-with-previously-treated-mantle-cell-lymphoma-24102017.html. Accessed: November 2017.

Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291–7.

Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486.

Finnes HD, Chaffee KG, Call TC, Ding W, Bowen DA, Conte M, et al. The importance of pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukaemia (CLL) in routine clinical practice. Blood 2015;126 (23):Abstract 717.

Flinn IW, Berdeja JG, Waselenko JK, Cooper RS, Bi J, Shih K, et al. Preliminary results from a phase I/II study of fludarabine, rituximab, and lenalidomide in untreated patients with chronic lymphocytic leukemia (CLL). Blood. 2010 (ASH Annual Meeting);116(21):Abstract 2461.

Flinn I, Brunvand M, Dyer MJ, Hillman P, Jones J, Lymp J, et al. Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood. 2014;124(21):4687

Flinn IW, Cherry M, Maris M, Matous JV, Berdeja JC, Manish R. Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia. Blood 2015;126(23).

Flinn I, Moreno C, Gill DS, Kipps TJ, Shaw Y, Li Y, et al. Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE. J Clin Oncol. 2015;33(Suppl):Abstract TPS7095.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al., Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–27.

Fraser G, Cramer P, Demirkan F, Silva RS, Pylypenko H, Grosicki S, et al. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A 2-year follow-up of the HELIOS study. J Clin Oncol 2016;34 suppl:Abstract 7525.

Freidberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578–85.

Furman RR, De Vos S, Leonard JP, Barrientos JC, Schreeder MT, Flinn IW, et al. A phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2013;122(21):Abstract 4180.

Furman R, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.

Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification and treatment. Am J Hematol. 2015;90:446–60.

Ibrutinib Summary of Product Characteristics. Janssen-Cilag Ltd, September 2017.

Ibrutinib Prescribing Information. Janssen Biotech Inc, August 2017.

Idelalisib Summary of Product Characteristics. Gilead Sciences Ltd, September 2017.

Idelalisib Prescribing Information. Gilead Sciences Inc, September 2017.

Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–50.

Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, et al. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(9):2154–8.

Jones JA, Hillmen P, Coutre S, Tam C, Furman RR, Barr PM, et al. Pattern of use of anticoagulation and/or antiplatelet agents in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Blood 2014;123(22):Abstract 1990.

Jones J, Mato AR, Coutre S, Wierda W, Choi MY, Davids MS, et al. Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/ GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukaemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. Blood 2015;126 (23):Abstract 715.

Jones J, Coutre S, Byrd JC (2016a). Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes. Presented at: 21st Congress of the European Hematology Association; June 9–12, 2016; Copenhagen, Denmark. Abstract S429.

Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem A (2016c). Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: A pooled population pharmacokinetic analysis. AAPS J. 2016;18:1192-202.

Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4(3):e114-e126.

Kashyap M, Amaya-Chanaga CI, Kumar M, Choi MY, Rassenti LZ, Ale-Ali A. et al. PF-06747143: an IgG1 anti-CXCR4 antibody induces apoptosis in chronic lymphocytic Leukemia. XVI International Workshop on Chronic Lymphocytic Leukemia 2015; Abstract 120.

Khan M, Saif A, Sandler S and Mirrakhimov AE. Idelalisib for the Treatment of Chronic Lymphocytic Leukaemia. ISRN Oncology. 2014; Volume 2014, Article ID 931858. http://dx.doi.org/10.1155/2014/931858.

Lampson BL, Kasar SN, Matos TR , Morgan EA , Rassenti L , Davids MS. et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203.

Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(6):1181–9.

Mato AR, Foon KA, Feldman T, Schuster SJ, Svoboda J, Chow KF, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol. 2015;90:489–92.

Mato A, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. Blood 2015;126 (23):Abstract 719.

National Comprehensive Cancer Network (NCCN) guidelines 2017. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Available from: http://www.nccn.org. Accessed:  November 2017.

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® Updated. Available from http://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=472 (accessed November 2017).

No authors listed. IPI-145 shows promise in CLL patients. Cancer Discov. 2014;4(2):136.

O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–94.

O’Brien S, Jones JA, Coutre S, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418.

O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15(1):48–58.

O'Brien S, Furman R, Fowler N, Coutre SE, Sharman JP, Blum KA, et al. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study. Blood. 2013;122(21).Abstract 4163.

Pagel NM, Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Updated efficacy including genetic subgroup analysis and overall safety in the phase 3 resonate trial of ibrutinib vs. ofatumumab in previously-treated chronic lymphocytic leukemia/small lymphocytic lymphoma. XVI International Workshop on Chronic Lymphocytic Leukemia 2015; Abstract 146.

Porter DL, Grupp SA, Kalos M, Loren AW, Lledo L, Gilmore J, et al. Chimeric antigen receptor T cells directed against CD19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL. Blood. 2012 (ASH Annual Meeting); 120(21):Abstract 717.

Porter DL, Kalos M, Frey NV, Grupp SA, Loren AW, Jemison C, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. Blood. 2013 (ASH Annual Meeting);122:Abstract 4162.

Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015;170:669–78.

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311–22.

Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–96.

Salles GA, Boyd TE, Morschhauser F, Wendtner C-M, Lymp J, Hilger J, et al. Preliminary results of a phase 1b study (GO28440) combining GDC-0199 (ABT-199) with bendamustine/rituximab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood. 2014;124(21):3337.

Savona M, Gutierrez M, Lanasa M, Deng C, Kuhn J, et al. A Phase 1 dose escalation study of TG-1202, a novel PI3Kδ Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2013;122(21).

Seymour J, Davids M, Pagel J, Kahl B, Wierda W, Miller T, et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). Hematol Oncol. 2013;31(Suppl 1):115.

Seymour JF, Kipps TJ, Eichhorst BF, Hillmen P, D’Rozario JM, Assouline S, et al. LBA-2 Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Abstract presentation at ASH Annual Meeting & Exposition December 12th 2017. Available from https://ash.confex.com/ash/2017/webprogram/Paper109076.html. Accessed December 2017.

Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, et al., An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125(15):2336–43.

Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010;51(1):85–8.

Stilgenbauer S, Eichhorst B, Schetelig B, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.

Stilgenbauer S, Furman RR, Zent CS. Management of Chronic Lymphocytic Leukemia. ASCO Educational Book 2015: 164–175. Available from: http://meetinglibrary.asco.org/EdBook. Accessed: 20th March 2015.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, et al. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia. 2016;30(2):337–45.

Venetoclax Prescribing Information. AbbVie Inc, April 2016.

Venetoclax Summary of Product Characteristics. Abbvie Ltd, July 2017.

Venetoclax Product Monograph. Abbvie Corporation, October 2016.

Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, et al., Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: Correlation between responses and immune characteristics. Clin Cancer Res. 2016;22(10):2359–67.

Vogler M, Dinsdale D, Dyer MJ, Cohen GM. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139–42.

Wendtner CM, Dreger P, Gregor M, Greil R, Knauf WU, Pritzkuleit R, et al. Chronic Lymphocytic Leukemia (CLL). Available from https://www.onkopedia-guidelines.info/en/onkopedia/guidelines/chronic-lymphocytic-leukemia-cll/@@view/html/index.html (accessed May 2017).

Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364–74.

Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov. 2009;4(1):28–35.

Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015;126(4):471–7.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, et al., Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311.